TREATMENT OF DRY EYE SYNDROME USING TANFANERCEPT OPHTHALMIC COMPOSITION

The present invention relates to treatment of dry eye syndrome using a Tanfanercept ophthalmic composition. According to the present invention, an ophthalmic composition containing Tanfanercept exhibited an excellent effect in improving the clinically important central corneal and total corneal staining score as a result of a clinical test for dry eye syndrome. In addition, the improvement of the central corneal and total corneal staining score was greater in patients having moderate to severe dry eyes, and the degree of improvement was also greater in patients having higher ocular discomfort indexes or dry eye indexes, which are subjective symptoms. It is an unexpected effect that the ophthalmic composition containing Tanfanercept exhibits superior efficacy in patients having more severe signs or symptoms despite the use of the same dose of Tanfanercept, and this is meaningful in terms of providing a new therapeutic alternative in consideration of the fact that there is no treatment for moderate to severe dry eye syndrome. La présente invention concerne le traitement du syndrome de l'œil sec à l'aide d'une composition ophtalmique de tanfanercept. Selon la présente invention, une composition ophtalmique contenant du tanfanercept présente un excellent effet sur l'amélioration du score important sur le plan clinique de coloration cornéenne centrale et totale dans le cadre d'un dépistage clinique du syndrome de l'œil sec. De plus, l'amélioration du score de coloration cornéenne centrale et totale a été plus grande chez des patients ayant des yeux secs modérés à sévères, et le degré d'amélioration est également supérieur chez des patients présentant des indices de gêne oculaire ou des indices d'œil sec supérieurs, qui sont des symptômes subjectifs. Un effet inattendu de la composition ophtalmique contenant du tanfanercept est son efficacité supérieure chez des patients présentant des signes ou des symptômes plus graves malgré l'utilisation de la même dose de tanfanercept, ce qui est pertinent dans la fourniture d'une nouvelle alternative thérapeutique en tenant compte du fait qu'il n'existe pas de traitement pour le syndrome de l'œil sec modéré à sévère. 본 발명은 탄파너셉트 안과용 조성물을 이용한 안구건조증의 치료에 관한 것이다. 본 발명에 따르면, 탄파너셉트 함유 안과용 조성물은 안구건조증에 대한 임상 시험 결과, 임상적으로 중요한 각막 중앙부와 각막 전체 합산 각막염색지수의 개선에 있어서 우수한 효과를 보였다. 또한, 이러한 각막 중앙부와 각막 전체 합산 각막 염색지수의 개선은 중등도 내지 중증 건성안을 갖는 환자에게서 더욱 크게 나타났으며, 주관적 증상인 안구불편감 지수나 안구건조감 지수가 더 높은 환자에게서도 개선의 정도가 더 큰 것으로 나타났다. 동일 용량의 탄파너셉트를 사용하였음에도 탄파너